As healthcare rapidly changes towards a patient-centric model, many opportunities exist to use the expertise of industry, govenernment and academia together to explore new approaches to drug discovery and healthcare. This talk will show how such an opportunity is being explored in an ongoing non-traditional collaboration involving Indiana University, NIH NCATS, Data2Discovery Inc and Eli Lilly that relates to phenotypic screening and drug repurposing. The collaboration products that will be described include the NIH Phenotypic Drug Discovery Resource (PDDR, https://ncats.nih.gov/expertise/preclinical/pd2) and a novel computational repurposing experiment for Tuberculosis.

Enabling precision drug repurposing through innovative public-private partnerships

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.